Acadia Pharmaceuticals (ACAD) Net Margin (2016 - 2025)
Historic Net Margin for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to 25.76%.
- Acadia Pharmaceuticals' Net Margin rose 126800.0% to 25.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.94%, marking a year-over-year increase of 111100.0%. This contributed to the annual value of 23.64% for FY2024, which is 320800.0% up from last year.
- Acadia Pharmaceuticals' Net Margin amounted to 25.76% in Q3 2025, which was up 126800.0% from 10.08% recorded in Q2 2025.
- Acadia Pharmaceuticals' 5-year Net Margin high stood at 55.37% for Q4 2024, and its period low was 97.95% during Q1 2022.
- Its 5-year average for Net Margin is 12.19%, with a median of 10.98% in 2021.
- Per our database at Business Quant, Acadia Pharmaceuticals' Net Margin tumbled by -355900bps in 2022 and then soared by 616300bps in 2023.
- Acadia Pharmaceuticals' Net Margin (Quarter) stood at 32.96% in 2021, then rose by 7bps to 30.53% in 2022, then skyrocketed by 165bps to 19.82% in 2023, then soared by 179bps to 55.37% in 2024, then tumbled by -53bps to 25.76% in 2025.
- Its Net Margin was 25.76% in Q3 2025, compared to 10.08% in Q2 2025 and 7.77% in Q1 2025.